Clinical Trial Detail

NCT ID NCT02519348
Title A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedImmune LLC
Indications

hepatocellular carcinoma

Therapies

Tremelimumab

Durvalumab

Age Groups: adult

No variant requirements are available.